Heyya people.. Any biotechnology freek? They can share me their views on the upcoming progress in biotechnology field.. Due to the corona outbreak!!! THANK YOU..
Answers
Answer:
7 countries are involved for making vaccine
Answer:
hope it helps.......actually I took this from an article.....if it heips plz mark it as brainliest
Explanation:
Genomics England and the GenOMICC (Genetics of Mortality in Critical Care) consortium are spearheading a human genome sequencing initiative that aims to analyze the genomes of tens of thousands of COVID-19 patients in the U.K. to try to understand how a person’s genes may affect how they react to the virus. The researchers will use the sequencing data to help provide new insights into the impact of genetic makeup on whether a patient will likely suffer only mild COVID-19 symptoms, or whether they are at risk of progressing to severe disease that requires hospitalization. The study will focus on people of all ages severely affected by COVID-19, including children and young adults.
“While we work with our NHS partners to enroll hospitalized patients, we are encouraging people who were previously in intensive care with COVID-19, or who are, or have recovered in the community from milder COVID-19 symptoms in the community, to register their interest in the study through the Genomics England website,” Scott said. “We think that this is the largest sequencing study of its kind, and we are very hopeful that the genomic data emerging will help us to better understand genetic risk factors associated susceptibility to severe disease. While we can’t predict what the data will show, we anticipate that emerging genetic insights could be used to help stratify patients for future clinical trials of COVID-19 therapies and vaccines.” The data could also ultimately inform on patient care, monitoring, and drug prescribing, Scott suggested.
The GenOMICC Consortium, led by Kenneth Baillie, MD, at the Roslin Institute, University of Edinburgh, will head enrollment for the sequencing initiative, and has obtained DNA samples from 2,000 intensive care COVID-19 patients, Scott further explained. “GenOMICC was set up in 2016 to sequence the genomes of patients with serious diseases, primarily flu and other emerging diseases, to help understand how genetics may influence disease outcomes and severity. The consortium of GenOMICC researchers had already begun recruiting patients with COVID-19 prior to the establishment of the sequencing initiative.”
Genomics England was established in 2013 to deliver the 100,000 genomes project in partnership with the NHS, which was completed in December 2018. The organization will provide the project infrastructure and know-how in terms of the large-scale genomic analyses, as well as coordinate the sequencing, and work as an enabler across the research landscapes to connect with other research groups who may want to join in the collaboration, Scott commented to GEN. “Genomics England is responsible for delivery of the sequencing components, the high-performance computing element, and for presenting the data for analysis in what we call a trusted research environment. More broadly, we are acting as a facilitator, and encouraging awareness of the research so that other researchers can be part of the work and the consortium.”
The physical sequencing will be carried out by Illumina, at the firm’s U.K. facility within the Wellcome Trust Sanger Institute, where Illumina carried out the sequencing for the 100,000 Genomes Project, together with Genomics England and the NHS. Illumina will sequence all of the 35,000 COVID-19 patient genomes at the U.K. facility, and will share some of the cost via in-kind contribution. “We have a long-standing partnership with Genomics England and are proud to support this new genomics initiative from our Cambridge-based lab,” commented Paula Dowdy, general manager and SVP, EMEA, Illumina, in a statement. “The results will establish a unique platform for researchers to understand the human response to coronavirus infection, leading towards new treatments and ways to control infection spread.”
Analysis of the genomes will be a joint effort, Scott further outlined to GEN. “We have the expertise to carry out the major bioinformatics ‘heavy lifting,’ and in performing key analyses.” The first core analysis will be a genome-wide association study (GWAS) to compare the genomes of mild- and the severe-COVID-19 disease patients, and this will be a joint effort between Genomics England and GenOMICC. “We will be looking for loci that might increase risk of severe disease, independent of other known risk factors,” Scott noted. “Importantly, our analyses will be done on an iterative basis, so we will carry out an initial analysis on small numbers of patients as their genomes are sequenced, and then repeat as the numbers of people who join the program grow.”